Page 336 of 440: studies 3,351 to 3,360 of 4,400, newest first. Back to the psilocybin overview
August 8, 2025 Gary Laderman 2 citations
Sacred Drugs explores the numerous ways in which psychoactive substances, from alcohol to psilocybin, cannabis to pharmaceuticals, and coffee to tobacco, intersect with religious life. This cutting-edge volume acknowledges the ubiquity of drug use in American society and that, in fact, being drugged with an altered state of consciousness is a common feature of American life today, as it has...
International Journal of Molecular Sciences August 7, 2025 Liliana Rebolledo-Pérez, Jorge Hernández‐bello, Alicia Martínez-ramos et al. 5 citations
Tau protein is essential for the structural stability of neurons, particularly through its role in microtubule assembly and axonal transport. However, when abnormally hyperphosphorylated or cleaved, Tau can aggregate into insoluble forms that disrupt neuronal function, contributing to the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD). Emerging evidence suggests...
Current Opinion in Psychology August 6, 2025 Iva Totomanova, Eline Haijen, Petra P M Hurks et al. 5 citations
Microdosing psychedelics, the regular use of low doses of LSD or psilocybin, have attracted growing public and scientific interest. This review synthesizes findings from 57 human studies on psychological and physiological outcomes in clinical and non-clinical populations. Reported benefits include improved mood, enhanced cognition, social functioning, and mental health, although findings are...
The International Journal of Neuropsychopharmacology August 1, 2025 Argel Aguilar-Valles, Dhiral Kot, Vern Lewis et al.
Abstract Background Major depressive disorder (MDD) is a multifactorial and heterogeneous disorder that affects around 280 million individuals worldwide, with approximately 80 million experiencing treatment-resistant depression (TRD). Neuronal hypotrophy and axon hypomyelination in the prefrontal cortex (PFC) are hallmark features of MDD, highlighting the need for treatments that address these...
The International Journal of Neuropsychopharmacology August 1, 2025 Bernard Lerer, Peretz Golding, Michal Brownstien et al.
Abstract Background We have designed a novel psychedelic-derived compound (HBL20017) characterized by high functional efficacy at 5-HT2A, 5-HT1A, and 5-HT2C receptors. We assessed its hallucinogenic properties and its potential for OCD treatment on the marble burying test (MBT) and in mice homozygous for deletion of the Synapse Associated Protein 3 (SAPAP3) gene. These mice manifest severe,...
The International Journal of Neuropsychopharmacology August 1, 2025 Guy M. Goodwin
Abstract Background Despite the widespread availability of multiple antidepressant treatments, depression remains a common and sometimes debilitating disorder. A significant proportion of patients with major depressive disorder fail two or more antidepressant treatments and are considered to have treatment-resistant depression (TRD). Recent attention has turned to psilocybin and other...
The International Journal of Neuropsychopharmacology August 1, 2025 Bernard Lerer, Michal Brownstien, Mitchell A. Lazar et al.
Abstract Background Obsessive-compulsive disorder (OCD) is associated with significant personal suffering and functional impairment. At least a third of OCD patients do not respond to conventional treatments. There is a substantial anecdotal literature suggesting that psychedelic agents, specifically psilocybin and psilocybin-containing psychedelic mushroom extract (PME), may be therapeutic in...
The International Journal of Neuropsychopharmacology August 1, 2025 Hiroe Tani
Abstract Background Psychedelics have long been explored as potential treatments for mental illnesses. Since the mid-20th century, clinical trials of psychedelics such as LSD for depression and anxiety in terminally ill patients have been conducted. In the 21st century, revived and accelerated efforts to promote the proper use of psychedelics in the medical field have led to increasingly...
Psychiatry Research August 1, 2025 Damian Swieczkowski, Aleksander Kwaśny, Krzysztof Sadko et al. 5 citations
Ketamine and its enantiomers, esketamine and arketamine, have emerged as promising treatments for treatment-resistant depression (TRD). This cross-sectional study evaluates the regulatory alignment of 40 clinical trials listed on ClinicalTrials.gov, focusing on the methodological challenges. The study highlights methodological inconsistencies, particularly around the challenges of functional...
Folia Medica Cracoviensia July 31, 2025 Krzysztof Ciszowski, Angelika Ziaja, Ewa Niedzielska-Andres et al.
Natural hallucinogens derived from fungi and animals have been used for centuries in shamanic, ritualistic, and medicinal practices across diverse cultures. These compounds exhibit a widerange of structures and mechanisms of action, affecting various neurotransmitter systems pathways. Fungal hallucinogens, primarily indole alkaloids like psilocybin and ergot alkaloids, as well as animal-derived...